Trade Novavax Inc - NVAX CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.09 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023512% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.00129% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 7.87 |
| Open | 7.87 |
| 1-Year Change | 94.32% |
| Day's Range | 7.78 - 8 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Feb 20, 2025 | 7.89 | -0.04 | -0.50% | 7.93 | 8.10 | 7.67 |
| Feb 19, 2025 | 7.93 | -0.27 | -3.29% | 8.20 | 8.20 | 7.86 |
| Feb 18, 2025 | 8.16 | -0.02 | -0.24% | 8.18 | 8.49 | 8.14 |
| Feb 14, 2025 | 8.15 | 0.06 | 0.74% | 8.09 | 8.48 | 7.91 |
| Feb 13, 2025 | 8.09 | 0.26 | 3.32% | 7.83 | 8.15 | 7.71 |
| Feb 12, 2025 | 7.82 | -0.27 | -3.34% | 8.09 | 8.12 | 7.76 |
| Feb 11, 2025 | 8.10 | -0.02 | -0.25% | 8.12 | 8.13 | 7.90 |
| Feb 10, 2025 | 8.10 | -0.07 | -0.86% | 8.17 | 8.31 | 8.03 |
| Feb 7, 2025 | 8.10 | -0.20 | -2.41% | 8.30 | 8.33 | 8.03 |
| Feb 6, 2025 | 8.30 | -0.25 | -2.92% | 8.55 | 8.73 | 8.21 |
| Feb 5, 2025 | 8.55 | 0.27 | 3.26% | 8.28 | 8.88 | 8.25 |
| Feb 4, 2025 | 8.44 | 0.06 | 0.72% | 8.38 | 8.65 | 8.11 |
| Feb 3, 2025 | 8.38 | 0.00 | 0.00% | 8.38 | 8.57 | 8.27 |
| Jan 31, 2025 | 8.66 | -0.26 | -2.91% | 8.92 | 9.13 | 8.51 |
| Jan 30, 2025 | 8.99 | 0.26 | 2.98% | 8.73 | 9.18 | 8.51 |
| Jan 29, 2025 | 8.75 | -0.62 | -6.62% | 9.37 | 9.64 | 8.73 |
| Jan 28, 2025 | 9.45 | 0.29 | 3.17% | 9.16 | 9.72 | 9.12 |
| Jan 27, 2025 | 9.16 | 0.18 | 2.00% | 8.98 | 9.58 | 8.87 |
| Jan 24, 2025 | 9.21 | -0.33 | -3.46% | 9.54 | 9.75 | 9.02 |
| Jan 23, 2025 | 9.45 | 0.64 | 7.26% | 8.81 | 9.59 | 8.52 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Novavax Company profile
Novavax Inc. (NVAX) is a biotechnology company that specialises in the discovery, development and commercialisation of innovative vaccines that prevent serious infectious diseases.
Headquartered in Maryland, United States, the company was founded in 1987.
It has developed a number of vaccines, including:
The Coronavirus vaccine NVX-CoV2373, currently in phase 3 trials.
The seasonal Influenza vaccine NanoFlu™ for adults over the age of 65, currently also in phase 3 trials.
The respiratory Syncytial Virus (RSV) vaccine ResVax™ for infants and maternal immunisation, currently in phase 3 trials, as well as two RSV F Vaccines, one for older adults (phase 2 trials) and one for children until the age of 5 (phase 1 trials).
The Ebola Virus vaccine Ebola GP Vaccine, currently in phase 1 trials.
The company develops its vaccines using genetically engineered three-dimensional nanostructures of recombinant proteins that are critical to disease pathogenesis.
The company is also working on producing immune-stimulating adjuvants at its wholly owned Swedish subsidiary Novavax AB.
Navavax’s key partners and collaborators include:
The Coalition for Epidemic Preparedness Innovations (CEPI), which has been funding the company to develop and manufacture its coronavirus vaccine candidate.
The Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND).
The Serum Institute of India (SII).
The 2009 joint venture with India’s privately held pharmaceutical company, Cadila Pharmaceuticals Ltd, to develop Novavax VLP vaccine candidates and some Cadila therapeutic vaccine candidates.
The company (ticker: NVAX) went public on the NASDAQ stock exchange in 1995.
| Industry: | Biotechnology & Medical Research (NEC) |
700 Quince Orchard Road
GAITHERSBURG
MARYLAND 20878
US
News
Microsoft Stock Price Forecast for 2025 and beyond: Third party price target
We assess the likely level of the Microsoft stock price in 5 years, and possible drivers behind the stock’s past performance. Read on...
18:29, 7 February 2025
Ripple XRP price prediction: Third-party price target
Discover the ripple (XRP) price predictions for 2025 and beyond, with analyst price targets and CFDs trading strategies on Capital.com
15:29, 6 February 2025
Apple (AAPL) stock price forecast: third-party price target
We looked at the forecasts for Apple stock in 10 years to see where the price would likely be at that point and the challenges the company could face. Read more.
11:22, 6 February 2025
FARTCOIN price prediction: Third-party price target
Read our FARTCOIN price prediction for 2025 and beyond, with insights from third-party analysts and market experts
10:18, 29 January 2025
MELANIA coin ($MELANIA) price prediction: Third party price target
Read our MELANIA crypto price prediction for 2025 and beyond, with insights from third-party analysts and market experts.
11:33, 22 January 2025
TRUMP coin ($TRUMP) price prediction: third-party price target
Read our TRUMP crypto price prediction for 2025 and beyond, with insights from third-party analysts and market experts
10:52, 22 January 2025
Ethereum price prediction: Third party data round up
What is the outlook for ETH as a long-term investment?
16:37, 7 January 2025People also watch
Still looking for a broker you can trust?
Join the 690,000+ traders worldwide that chose to trade with Capital.com